Oncolytics Biotech Stock Price, News & Analysis (TSE:ONC) C$1.90 +0.01 (+0.53%) (As of 12/5/2023 ET) Add Compare Share Share Today's RangeC$1.86▼C$1.9150-Day RangeC$1.82▼C$2.9952-Week RangeC$1.48▼C$4.49Volume30,606 shsAverage Volume110,152 shsMarket CapitalizationC$139.46 millionP/E RatioN/ADividend Yield0.31%Price TargetC$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades About Oncolytics Biotech Stock (TSE:ONC)Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comOncolytics Biotech (TSE:ONC) Stock Passes Below 200 Day Moving Average of $2.82November 9, 2023 | finance.yahoo.comOncolytics Provides Update on Pancreatic Cancer Program for PelareorepDecember 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | benzinga.comOncolytics Biotech's Earnings OutlookNovember 3, 2023 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational HighlightsNovember 3, 2023 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCNovember 3, 2023 | finance.yahoo.comOncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCNovember 3, 2023 | msn.comOncolytics Biotech GAAP EPS of -$0.14 misses by $0.06December 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | finance.yahoo.comOncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational HighlightsOctober 23, 2023 | marketwatch.comOncolytics Shares Rise 9.3% as Data Presented From Pancreatic Cancer StudyOctober 20, 2023 | finanznachrichten.deUSA News Group: Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment ResearchOctober 20, 2023 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational HighlightsSeptember 28, 2023 | ca.finance.yahoo.comStocks in play: Oncolytics Biotech, Inc.September 22, 2023 | baystreet.caPioneering the Path to Cure Cancer: 2023's Biotech InnovationsSeptember 20, 2023 | finanznachrichten.deUSA News Group: On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting HopeSeptember 13, 2023 | msn.comOncolytics Biotech: Is The Early Data Really That Good?August 29, 2023 | finance.yahoo.com3 Under-$20 Stocks to Buy for Explosive ReturnsAugust 18, 2023 | markets.businessinsider.comJonesTrading downgrades TRACON Pharmaceuticals (TCON) to a HoldAugust 14, 2023 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational HighlightsAugust 14, 2023 | msn.comOncolytics Biotech GAAP EPS of -C$0.12August 14, 2023 | finance.yahoo.comOncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational HighlightsAugust 3, 2023 | markets.businessinsider.comJonesTrading Remains a Buy on Cassava Sciences (SAVA)July 31, 2023 | marketwatch.comOncolytics Biotech Stock Down 15% on Deal for Discounted OfferingJuly 31, 2023 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of UnitsJuly 31, 2023 | finance.yahoo.comOncolytics Biotech® Announces US$15 Million Bought Deal Offering of UnitsJuly 26, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Gossamer Bio (GOSS)See More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2023Today12/06/2023Next Earnings (Estimated)3/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:ONC CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price TargetC$9.00 High Stock Price TargetC$9.00 Low Stock Price TargetC$9.00 Potential Upside/Downside+373.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-32,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.71% Return on Assets-49.16% Debt Debt-to-Equity Ratio1.77 Current Ratio4.53 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.45 per share Price / Cash Flow4.22 Book ValueC$0.40 per share Price / Book4.75Miscellaneous Outstanding Shares73,400,000Free FloatN/AMarket CapC$139.46 million OptionableNot Optionable Beta1.74 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerMr. Andrew R. de Guttadauro (Age 56)Global Head of Business Development & President of Oncolytics Biotech (U.S.) Inc Comp: $634.74kDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen F.C.A.FCA, LLD, ConsultantMore ExecutivesKey CompetitorsImmunoPrecise AntibodiesCVE:IPABriaCell TherapeuticsTSE:BCTScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMNovoheartCVE:NVHView All Competitors ONC Stock Analysis - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONC shares. View ONC analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price target for 2024? 3 brokerages have issued 12-month target prices for Oncolytics Biotech's shares. Their ONC share price targets range from C$9.00 to C$9.00. On average, they predict the company's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 373.7% from the stock's current price. View analysts price targets for ONC or view top-rated stocks among Wall Street analysts. How have ONC shares performed in 2023? Oncolytics Biotech's stock was trading at C$2.22 at the beginning of 2023. Since then, ONC shares have decreased by 14.4% and is now trading at C$1.90. View the best growth stocks for 2023 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024. View our ONC earnings forecast. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) issued its quarterly earnings results on Friday, November, 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR). How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:ONC) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.